Neoadjuvant Pembrolizumab for Stage 3 Head and Neck Squamous Cell Cancer Who May Benefit
For many people with stage 3 head and neck squamous cell carcinoma, surgery is only one part of treatment. The harder question is what should happen before and after surgery to lower the risk of the cancer coming back.
Pembrolizumab, a PD-1 checkpoint inhibitor, has already changed treatment for recurrent or metastatic head and neck cancer. The newer question is whether it can help earlier, when the cancer is still considered curable and surgery is planned. This is where neoadjuvant treatment, therapy given before surgery, has become one of the most closely watched areas in head and neck oncology.
Recent clinical trial data support a perioperative approach in selected patients: pembrolizumab before surgery, followed by standard surgery, then pembrolizumab again after surgery with postoperative radiotherapy, with or without chemotherapy depending on risk features. This is not a simple “add-on”. It changes the whole treatment pathway and needs careful patient selection.
This article explains who may benefit, what the trial approach looks like, and what clinicians and patients should think through before choosing neoadjuvant pembrolizumab.
What neoadjuvant pembrolizumab means in stage 3 head and neck cancer
Neoadjuvant therapy is treatment given before the main local treatment, which is usually surgery in resectable head and neck squamous cell carcinoma. In this setting, pembrolizumab is given while the tumour is still in place.
That matters because the immune system can “see” the tumour and its antigens before it is removed. The theory is that pembrolizumab may help activate anti-tumour T cells while there is still enough tumour present to educate the immune response. After surgery, continued treatment may help control microscopic disease that cannot be seen on scans or under the surgeon’s eye.
The term perioperative pembrolizumab is often used because treatment is given on both sides of surgery:
Before surgery Pembrolizumab is given as neoadjuvant treatment.
During definitive local treatment Surgery removes the primary tumour and involved lymph nodes where appropriate.
After surgery Pembrolizumab is continued as adjuvant treatment, usually alongside or after postoperative radiotherapy, and sometimes with cisplatin-based chemotherapy if the pathology shows high-risk features.
This approach is different from using pembrolizumab only in recurrent or metastatic disease. The aim is not disease control alone. The aim is cure, or at least a higher chance of long-term disease-free survival.
The growing focus on neoadjuvant immunotherapy in head and neck cancer squamous cell stage 3 reflects a wider shift in oncology: treating micrometastatic disease earlier, when the immune system may be more capable of mounting an effective response.
Why stage 3 disease is a key group to consider
Stage 3 head and neck squamous cell carcinoma sits in a difficult middle ground. The cancer is usually still treated with curative intent, but the risk of recurrence can be meaningful, especially when nodal disease, adverse pathology, or biologically aggressive features are present.
Stage 3 disease may include tumours that are larger, have spread to regional lymph nodes, or both. The exact staging depends on the tumour site, HPV status in oropharyngeal cancer, tumour size, depth of invasion, nodal burden, extranodal extension, and other anatomical details.
This matters because “stage 3” is not one uniform group. A small HPV-positive oropharyngeal tumour with limited nodal disease is not the same as a bulky oral cavity cancer with multiple involved lymph nodes. Both may be labelled stage 3 in some contexts, but their biology, treatment options, and expected outcomes may differ.
People most likely to be discussed for perioperative pembrolizumab are usually those with:
Resectable, locally advanced squamous cell carcinoma
A treatment plan that already includes surgery
A risk profile where recurrence remains a serious concern
Adequate fitness for a combined treatment course
No major contraindication to immune checkpoint blockade
The possible benefit becomes more compelling when the planned treatment already includes surgery followed by radiotherapy or chemoradiotherapy. In that situation, perioperative pembrolizumab may be considered as part of an intensified curative strategy, not as a replacement for proven local treatment.
What recent clinical trial evidence suggests
The main trial concept behind this approach is straightforward: compare standard curative treatment with or without pembrolizumab given before and after surgery.
In the perioperative pembrolizumab strategy, patients with resectable, locally advanced head and neck squamous cell carcinoma receive pembrolizumab before surgery. They then undergo surgery. After surgery, they receive adjuvant pembrolizumab with postoperative radiotherapy, and chemotherapy is added when standard pathology-based indications are present.
Recent phase 3 trial results have reported an improvement in event-free survival with this perioperative approach in the overall study population, with particular interest in patients whose tumours express PD-L1. Event-free survival generally means the length of time before events such as recurrence, progression, inability to undergo planned surgery, or death.
That endpoint is important in curative-intent head and neck cancer because recurrence can be hard to treat and may affect speech, swallowing, breathing, nutrition, and quality of life.
The trial findings also support a practical message: pembrolizumab before surgery did not replace surgery. The benefit came from a planned sequence of treatment, with systemic immune therapy added around definitive local care.
The key idea is not simply “give pembrolizumab early”. It is to select patients who can complete a coordinated pathway of neoadjuvant therapy, surgery, and risk-adapted adjuvant treatment.
There are still details that clinicians need to interpret carefully, including the size of benefit in different subgroups, the role of PD-L1 expression, long-term overall survival, surgical timing, toxicity, and quality-of-life outcomes. But the direction of evidence has made perioperative pembrolizumab a serious option for selected patients with resectable locally advanced disease.
Who may benefit most from neoadjuvant pembrolizumab
The best candidates are not defined by stage alone. Selection usually depends on tumour factors, patient factors, surgical planning, and immune-related risk.
Patients with resectable locally advanced disease
Pembrolizumab before surgery makes sense only if surgery remains feasible and planned. If the tumour is not resectable, or if the primary treatment plan is definitive chemoradiotherapy rather than surgery, the evidence and decision-making are different.
Potential candidates often include patients with cancers of the:
Oral cavity
Oropharynx
Larynx
Hypopharynx
The exact role may differ by site. Oral cavity cancer, for example, is commonly treated with surgery first when resectable. Some oropharyngeal cancers may be treated with surgery or definitive chemoradiotherapy depending on anatomy, HPV status, function, and local expertise.
Patients at higher risk of recurrence
A perioperative approach is most attractive when recurrence risk is high enough to justify extra systemic treatment.
Higher-risk features may include:
Large primary tumour
Clinically involved lymph nodes
Multiple suspicious nodes
Bulky nodal disease
Concern for extranodal extension
Close relationship to critical structures
Aggressive clinical behaviour
Smoking-related disease biology in some settings
Some of the most important risk features, such as positive margins or extranodal extension, are only confirmed after surgery. That is why postoperative treatment is still guided by final pathology.
Patients whose tumours express PD-L1
PD-L1 testing may help estimate the chance of benefit from pembrolizumab, although it is not the only factor. Trials of checkpoint inhibitors often analyse benefit by PD-L1 expression, commonly reported through a combined positive score, or CPS.
In general, tumours with higher PD-L1 expression may be more likely to respond to PD-1 blockade. Still, PD-L1 is an imperfect biomarker. Some PD-L1-positive tumours do not respond, and some tumours with low expression may still show immune sensitivity.
PD-L1 should be used as part of the conversation, not as the whole conversation.
Patients fit enough for the full pathway
Perioperative treatment asks a lot from the patient. It requires time, coordination, monitoring, surgery, wound healing, and postoperative treatment. A person who is frail, severely malnourished, or medically unstable may face more risk than benefit.
Before treatment, teams often assess:
Nutrition and weight loss
Swallowing function
Airway safety
Dental health
Kidney function if chemotherapy may be needed
Hearing if cisplatin is being considered
Autoimmune history
Steroid use
Performance status
Social support and ability to attend frequent appointments
The goal is not to exclude people unnecessarily. It is to avoid starting a plan that cannot be safely completed.
Who may not be a good candidate
Pembrolizumab can cause durable benefit, but it can also cause immune-related side effects. These happen when the immune system attacks normal tissues.
People may need extra caution, or may not be suitable, if they have:
Active autoimmune disease needing systemic treatment
Previous serious immune-related toxicity from checkpoint inhibitors
An organ transplant
Uncontrolled infection
Severe frailty or poor performance status
A need for high-dose long-term steroids
Medical issues that make surgery unsafe
Disease where delaying surgery would be dangerous
Possible immune-related side effects include inflammation of the thyroid, lungs, bowel, liver, skin, adrenal glands, kidneys, or other organs. Some are mild and treatable. Others can be serious or long lasting.
Timing is also important. If a tumour is threatening the airway, bleeding, or progressing rapidly, the team may decide that immediate local treatment is safer than adding preoperative therapy.
How treatment may be sequenced in practice
A perioperative pembrolizumab plan usually begins with a multidisciplinary review. Head and neck cancer treatment is too complex for one specialty to decide alone.
The core team may include:
Head and neck surgeon
Medical oncologist
Clinical oncologist or radiation oncologist
Radiologist
Pathologist
Specialist nurse
Dietitian
Speech and language therapist
Restorative dentist
Anaesthetist where needed
The pathway may look like this.
Stage of care | What usually happens |
Diagnosis and staging | Biopsy confirms squamous cell carcinoma. Imaging defines local and nodal extent. HPV and PD-L1 testing may be requested where relevant. |
Multidisciplinary decision | The team confirms whether the cancer is resectable and whether perioperative pembrolizumab is appropriate. |
Neoadjuvant pembrolizumab | Pembrolizumab is given before surgery according to the trial-based schedule used by the treating centre. |
Surgery | The primary tumour and involved neck nodes are removed as planned. Reconstruction may be needed depending on the site and extent. |
Pathology review | Margins, nodal disease, extranodal extension, perineural invasion, lymphovascular invasion, and treatment response are assessed. |
Adjuvant therapy | Pembrolizumab continues after surgery. Postoperative radiotherapy is given, with chemotherapy added for standard high-risk indications. |
Surveillance | Follow-up checks for recurrence, late side effects, swallowing, speech, nutrition, thyroid function, and quality of life. |
The strongest treatment plans protect the timing of surgery. Neoadjuvant therapy should not create avoidable delays, particularly in cancers where local growth can quickly affect function.
What response before surgery can and cannot tell us
One appeal of neoadjuvant treatment is that it allows doctors to study the tumour after exposure to pembrolizumab. The surgical specimen can show whether immune therapy caused tumour cell death, immune infiltration, or a pathological response.
A strong pathological response may be encouraging. It can suggest that the immune system recognised and attacked the cancer.
But response assessment is not yet simple enough to make all later treatment decisions automatic. A visible shrinkage on scans is helpful, but it may not capture the full immune effect. By contrast, inflammation caused by immune activation can sometimes make imaging harder to interpret.
At present, surgery and pathology remain essential. Even if the tumour appears smaller after pembrolizumab, planned surgery usually still goes ahead unless there is a clear medical reason to change course.
The same applies after surgery. A good response does not automatically mean radiotherapy can be omitted. De-intensifying adjuvant treatment is an area of research, but it should not be assumed outside a carefully defined protocol.
Balancing benefit with side effects and function
Head and neck cancer treatment affects daily life in unusually direct ways. It can change speech, swallowing, taste, saliva, appearance, breathing, dental health, and nutrition. Any new treatment must be judged not only by cancer outcomes, but also by the burden it adds.
Pembrolizumab does not usually cause the same side effects as chemotherapy. Hair loss and severe nausea are less typical. Yet immune toxicity can be unpredictable. A patient may feel well for several cycles and then develop diarrhoea, breathlessness, liver inflammation, or hormone problems.
Adjuvant radiotherapy and chemotherapy can also cause:
Sore mouth and throat
Swallowing pain
Dry mouth
Skin reaction
Fatigue
Weight loss
Feeding tube requirement in some cases
Long-term swallowing stiffness
Dental complications
Reduced thyroid function
Adding pembrolizumab may increase monitoring needs. It may also complicate the assessment of symptoms. For example, fatigue after radiotherapy is common, but fatigue can also signal thyroid or adrenal inflammation.
This is why early reporting matters. A new cough, diarrhoea, jaundice, severe fatigue, headache, rash, or shortness of breath should be reported promptly during and after treatment.
Questions to ask before starting neoadjuvant pembrolizumab
A good discussion should be specific to the tumour, the patient, and the planned operation. Useful questions include:
Is the cancer clearly resectable?
What is the goal of adding pembrolizumab before surgery?
Does the tumour express PD-L1, and how does that affect the decision?
Will this treatment delay surgery?
What side effects should trigger an urgent call?
What happens if the tumour grows during neoadjuvant treatment?
Will postoperative radiotherapy still be needed?
When would chemotherapy be added after surgery?
How will swallowing, speech, and nutrition be supported?
Is this approach part of local standard care or a clinical trial pathway?
These questions help clarify whether treatment is being offered because the expected benefit is meaningful, or because it is available and new. That distinction matters.
The practical takeaway
Neoadjuvant pembrolizumab is becoming an important option for selected people with resectable stage 3 head and neck squamous cell carcinoma, especially when the cancer is locally advanced and recurrence risk is a major concern. The most promising approach is perioperative: pembrolizumab before surgery, then surgery, then adjuvant pembrolizumab with postoperative radiotherapy, with chemotherapy added when pathology shows high-risk disease.
The patients most likely to benefit are those with resectable disease, adequate fitness, a realistic plan to complete surgery and adjuvant treatment, and tumour features suggesting enough recurrence risk to justify treatment intensification. PD-L1 expression may support the case, but it should not be the only factor.
This is a specialist decision. It belongs in a multidisciplinary head and neck cancer team, with careful attention to timing, immune-related side effects, surgical outcomes, swallowing, speech, and long-term quality of life.
Medical information here is for general education only. Individual treatment decisions should be made with the treating oncology and surgical team, based on staging, pathology, imaging, overall health, and local treatment protocols.
Comments